share_log

基石藥業-B：截至二零二四年一月三十一日止月份之股份發行人的證券變動月報表

CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024

香港交易所 ·  Feb 6 06:01
Summary by Moomoo AI
基石藥業於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的資料。報告顯示，公司的法定/註冊股本維持不變，上月底結存及本月底結存均為2,000,000,000股，每股面值0.0001美元，總額為200,000美元。此外，基石藥業的股份期權計劃中，2017年7月7日採納的首次公開發售前激勵計劃及2019年1月30日採納的首次公開發售後僱員持股計劃均無本月內變動。後者在本月內有1,351,308股份期權失效，但仍有71,796,186股份期權結存，並可能發行新股份數目為98,423,245股。公司確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
基石藥業於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的資料。報告顯示，公司的法定/註冊股本維持不變，上月底結存及本月底結存均為2,000,000,000股，每股面值0.0001美元，總額為200,000美元。此外，基石藥業的股份期權計劃中，2017年7月7日採納的首次公開發售前激勵計劃及2019年1月30日採納的首次公開發售後僱員持股計劃均無本月內變動。後者在本月內有1,351,308股份期權失效，但仍有71,796,186股份期權結存，並可能發行新股份數目為98,423,245股。公司確認，所有證券發行均已獲董事會授權，並符合香港聯合交易所有限公司證券上市規則的要求。
KEYSTONE PHARMACEUTICALS SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 FEBRUARY 2024, COVERING DATA AS OF 31 JANUARY 2024. The report shows that the company's regulated/registered share capital remained unchanged, with 2,000,000,000 shares outstanding at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share, totaling $200,000. IN ADDITION, THE INITIAL PUBLIC PRE-SALE INCENTIVE PLAN ADOPTED ON 7 JULY 2017 AND THE INITIAL PUBLIC POST-SALE EMPLOYEE SHAREHOLDING PLAN ADOPTED ON 30 JANUARY 2019 WERE ALSO UNCHANGED DURING THE MONTH. The latter had 1,351,308 share options expired this month, but still had 71,796,186 share options outstanding and a possible issue of 98,423,245 shares. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
KEYSTONE PHARMACEUTICALS SUBMITTED ITS LATEST SECURITIES MONTHLY CHANGE REPORT TO HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 FEBRUARY 2024, COVERING DATA AS OF 31 JANUARY 2024. The report shows that the company's regulated/registered share capital remained unchanged, with 2,000,000,000 shares outstanding at the end of last month and deposits at the end of this month, with a face value of $0.0001 per share, totaling $200,000. IN ADDITION, THE INITIAL PUBLIC PRE-SALE INCENTIVE PLAN ADOPTED ON 7 JULY 2017 AND THE INITIAL PUBLIC POST-SALE EMPLOYEE SHAREHOLDING PLAN ADOPTED ON 30 JANUARY 2019 WERE ALSO UNCHANGED DURING THE MONTH. The latter had 1,351,308 share options expired this month, but still had 71,796,186 share options outstanding and a possible issue of 98,423,245 shares. The Company confirms that all securities issuance has been authorised by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more